Ignyte Acquisition Corp. IGNY 深 沪
已收盘 11-01 16:00:00 美东时间
13.05
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 13.05
- 总市值 9510.19万
- 52周最高 15.00
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 8.62
- 委 比 0.00%
- 总股本 728.75万
- 历史最高 15.00
- 量 比 0
- 振 幅 0.00%
- 历史最低 8.62
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Replimune To Contact Him Directly To Discuss Their Option...
09-13 22:10
Why Is Replimune Stock Trading Lower On Monday?
Replimune stock falls as FDA denies skin cancer drug approval and investors sue over alleged misstatements tied to the IGNYTE trial.
08-05 00:43
Replimune Faces Investor Lawsuit Over IGNYTE Trial
In a dramatic turn of events, Replimune Group, Inc. finds itself at the center ...
07-30 03:15
Iovance climbs after FDA rejection for Replimune’s skin cancer drug
The FDA’s decision to reject Replimune’s (NASDAQ:REPL) lead asset RP1 for a type of skin cancer known as melanoma appears to have boosted its rival, Iovance Biotherapeutics (NASDAQ:IOVA), whose lead p...
07-22 22:54
FDA Rejects Replimune's Blood Cancer Drug, Stock Sinks
Replimune stock fell after the FDA rejected its RP1 application, citing flaws in the trial design and lack of substantial evidence for approval.
07-22 21:41
FDA Rejects Replimune's Skin Cancer Drug, Stock Sinks (CORRECTED)
Replimune stock fell after the FDA rejected its RP1 application, citing flaws in the trial design and lack of substantial evidence for approval.
07-22 21:41
Adaptimmune targets $400M sarcoma franchise peak sales by 2027
Earnings Call Insights: Adaptimmune Therapeutics (ADAP) Q4 2024 Management View CEO Adrian Rawcliffe highlighted the accelerated progress of the TECELRA launch, emphasizing that the company has alread...
03-21 00:10
Replimune to raise ~$100M in private financing
Replimune Group (NASDAQ:REPL) said on Thursday it entered into a securities purchase agreement for a private investment in public equity ("PIPE"). The biotechnology company will issue and sell 5,668,9...
2024-06-13 21:47
S&P 500 Edges Lower; J. M. Smucker Shares Surge Following Earnings Beat
U.S. stocks traded mixed toward the end of trading, with the S&P 500 fallin...
2024-06-07 02:45
Crude Oil Jumps 2%; Lululemon Posts Upbeat Earnings
U.S. stocks traded mixed midway through trading, with the Dow Jones index gaini...
2024-06-07 00:22
